Shire plots an AD­HD pub­lic spin­off as CEO Orn­skov com­pletes a top-to-bot­tom over­haul

Hard on the heels of win­ning an ap­proval for its long-last­ing ver­sion of Adder­all for AD­HD, Shire says it’s now con­sid­er­ing spin­ning off its block­buster fran­chise drugs in that field in­to a new pub­lic com­pa­ny, mark­ing a fi­nal re­struc­tur­ing that will leave the Boston-based biotech fo­cused on rare dis­eases.

Shire said in its Q2 state­ment Thurs­day morn­ing that the com­pa­ny has been do­ing a strate­gic re­view of its neu­ro­sciences di­vi­sion, con­sid­er­ing its op­tions on how best to han­dle the fran­chise, and says that a pub­lic list­ing is one big op­tion. Shire’s stock $SH­PG jumped more than 3% on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER